A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Platinum-Doublet Chemotherapy or Immunotherapy in Subjects With Advanced Non-Small Cell Lung Cancer/Extensive-Disease Small Cell Lung Cancer.
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 08 Aug 2017 Planned End Date changed from 22 Jun 2019 to 15 Dec 2019.
- 03 Jan 2017 Planned number of patients changed from 48 to 75.
- 19 Oct 2016 Planned End Date changed from 1 Dec 2017 to 1 Jun 2019.